JP Morgan Chase
SVA

JP Morgan Chase’s Sinovac Biotech, Ltd SVA Stock Holding History

JP Morgan Chase’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,000
Closed -$19.4K – 7916
2024
Q1 		$19.4K Buy
+3,000
New +$19.4K ﹤0.01% 6235
2023
Q4 		– Sell
-3,000
Closed -$19.4K – 8125
2023
Q3 		$19.4K Hold
3,000
– – ﹤0.01% 6077
2023
Q2 		$19.4K Buy
+3,000
New +$19.4K ﹤0.01% 5922
2022
Q4 		– Sell
-3,000
Closed -$19K – 7417
2022
Q3 		$19K Hold
3,000
– – ﹤0.01% 5830
2022
Q2 		$19K Buy
+3,000
New +$19K ﹤0.01% 5912
2022
Q1 		– Sell
-3,000
Closed -$19K – 7370
2021
Q4 		$19K Hold
3,000
– – ﹤0.01% 6240
2021
Q3 		$19K Hold
3,000
– – ﹤0.01% 6066
2021
Q2 		$19K Hold
3,000
– – ﹤0.01% 5944
2021
Q1 		$19K Buy
+3,000
New +$19K ﹤0.01% 5714
2020
Q4 		– Sell
-400
Closed -$3K – 6214
2020
Q3 		$3K Hold
400
– – ﹤0.01% 5373
2020
Q2 		$3K Hold
400
– – ﹤0.01% 5254
2020
Q1 		$3K Buy
+400
New +$3K ﹤0.01% 5175
2017
Q2 		– Sell
-564
Closed -$3K – 5538
2017
Q1 		$3K Sell
564
-852
-60% -$4.93K ﹤0.01% 4949
2016
Q4 		$8K Sell
1,416
-3,090
-69% -$18.6K ﹤0.01% 4830
2016
Q3 		$27K Buy
4,506
+3,984
+763% +$23.4K ﹤0.01% 4147
2016
Q2 		$3K Sell
522
-259
-33% -$1.59K ﹤0.01% 4590
2016
Q1 		$5K Buy
781
+220
+39% +$1.32K ﹤0.01% 4393
2015
Q4 		$3K Buy
+561
New +$3.02K ﹤0.01% 4503

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase's SVA Position: Q2 2024 in Review

JP Morgan Chase sold out of Sinovac Biotech, Ltd (SVA) in Q2 2024, closing a stake of 3,000 shares — an estimated $19.4K sold.

JP Morgan Chase first reported a position in SVA in Q4 2015 and held it in 18 quarters. The position peaked at $27K in Q3 2016. 26 funds tracked by Wall St. Rank hold SVA as of Q2 2024.

  • JP Morgan Chase reported no remaining Sinovac Biotech, Ltd position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 3,000 Sinovac Biotech, Ltd shares in Q2 2024, an estimated $19.4K.
  • JP Morgan Chase first reported a position in Sinovac Biotech, Ltd in Q4 2015 and held it in 18 quarters.
  • JP Morgan Chase's Sinovac Biotech, Ltd position peaked at $27K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.